Works matching DE "ERENUMAB"

Results: 202

Efficacy and safety of erenumab in women with a history of menstrual migraine.

Published in:

Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01167-6

By:

Pavlovic, Jelena M.;
Paemeleire, Koen;
Göbel, Hartmut;
Bonner, Jo;
Rapoport, Alan;
Kagan, Risa;
Zhang, Feng;
Picard, Hernan;
Mikol, Daniel D.

Publication type:

Article

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.

Published in:

Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01151-0

By:

Scheffler, Armin;
Messel, Olga;
Wurthmann, Sebastian;
Nsaka, Michael;
Kleinschnitz, Christoph;
Glas, Martin;
Naegel, Steffen;
Holle, Dagny

Publication type:

Article

A prospective real-world analysis of erenumab in refractory chronic migraine.

Published in:

Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01127-0

By:

Lambru, Giorgio;
Hill, Bethany;
Murphy, Madeleine;
Tylova, Ivona;
Andreou, Anna P.

Publication type:

Article

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

Published in:

Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01102-9

By:

Ornello, Raffaele;
Casalena, Alfonsina;
Frattale, Ilaria;
Gabriele, Amleto;
Affaitati, Giannapia;
Giamberardino, Maria Adele;
Assetta, Maurizio;
Maddestra, Maurizio;
Marzoli, Fabio;
Viola, Stefano;
Cerone, Davide;
Marini, Carmine;
Pistoia, Francesca;
Sacco, Simona

Publication type:

Article

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.

Published in:

Journal of Headache & Pain, 2019, v. 20, n. 1, p. N.PAG, doi. 10.1186/s10194-019-1054-4

By:

Ornello, Raffaele;
Tiseo, Cindy;
Frattale, Ilaria;
Perrotta, Giulia;
Marini, Carmine;
Pistoia, Francesca;
Sacco, Simona

Publication type:

Article

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.

Published in:

Journal of Headache & Pain, 2019, v. 20, n. 1, p. N.PAG, doi. 10.1186/s10194-019-1018-8

By:

Raffaelli, Bianca;
Mussetto, Valeria;
Israel, Heike;
Neeb, Lars;
Reuter, Uwe

Publication type:

Article

Erenumab Induces Remission in Chronic Migraine Medication Overuse Headache.

Published in:

Patient Care (Online), 2024, p. 6

By:

Halsey, Grace

Publication type:

Article

Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis.

Published in:

Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2024.1342111

By:

Shijie Wei;
Hao Lv;
Dianhui Yang;
Lili Zhang;
Xuhao Li;
Yike Ning;
Yu Tang;
Xinyu Wu;
Jing Han

Publication type:

Article

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the effcacy?

Published in:

Frontiers in Neurology, 2023, p. 1, doi. 10.3389/fneur.2023.1176816

By:

Uzun, Sena;
Frejvall, Ulf;
Özkaya-Sahin, Gülsen;
Sahin, Gürdal

Publication type:

Article

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.

Published in:

Frontiers in Neurology, 2023, v. 14, p. 1, doi. 10.3389/fneur.2023.1154420

By:

Overeem, Lucas Hendrik;
Lange, Kristin Sophie;
Fitzek, Mira Pauline;
Siebert, Anke;
Steinicke, Maureen;
Triller, Paul;
Hong, Ja Bin;
Reuter, Uwe;
Raaelli, Bianca

Publication type:

Article

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab.

Published in:

European Neurology, 2023, v. 86, n. 2, p. 135, doi. 10.1159/000527674

By:

Bolchini, Marco;
Schiano di Cola, Francesca;
Ceccardi, Giulia;
Caratozzolo, Salvatore;
Liberini, Paolo;
Rao, Renata;
Padovani, Alessandro

Publication type:

Article

Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series.

Published in:

2022

By:

Patier Ruiz, Ignacio;
Sánchez-Rubio Ferrández, Javier;
Cárcamo Fonfría, Alba;
Molina García, Teresa

Publication type:

Case Study

Efficacy and Tolerability of Erenumab and Topiramate for Prevention of Chronic Migraine: A Retrospective Cohort Study.

Published in:

Medicina (1010660X), 2024, v. 60, n. 10, p. 1684, doi. 10.3390/medicina60101684

By:

Nebrisi, Eslam El;
Ruwayya, Zainaba Suaad Ahmed;
Alzayori, Dalya Ibrahim;
Alzayori, Ranya Ibrahim;
Chandran, Shyam Babu;
Elshafei, Mohamed

Publication type:

Article

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine.

Published in:

Medicina (1010660X), 2023, v. 59, n. 9, p. 1560, doi. 10.3390/medicina59091560

By:

Lovato, Andrea;
Disco, Caterina;
Frosolini, Andrea;
Monzani, Daniele;
Perini, Francesco

Publication type:

Article

Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.

Published in:

BMC Neurology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12883-023-03521-y

By:

Shibata, Mamoru;
Fujita, Kazuki;
Hoshino, Eri;
Minami, Kazushi;
Koizumi, Kenzo;
Okada, Satoshi;
Sakai, Fumihiko

Publication type:

Article

Evaluation of the change in efficacy of erenumab when used long‐term for migraine prevention after initial established benefit in a veteran population.

Published in:

Pharmacotherapy, 2023, v. 43, n. 6, p. 494, doi. 10.1002/phar.2812

By:

Martin, Alison W.;
Cubellis, Mara

Publication type:

Article

Alopecia signals associated with calcitonin gene‐related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study.

Published in:: Pharmacotherapy, 2022, v. 42, n. 10, p. 758, doi. 10.1002/phar.2725
Publication type:: Article

Myocardial infarction associated with erenumab: A case report.

Published in:

Pharmacotherapy, 2022, v. 42, n. 7, p. 585, doi. 10.1002/phar.2706

By:

Perino, Justine;
Corand, Virginie;
Laurent, Elise;
Théophile, Hélène;
Miremont‐Salamé, Ghada;
Pariente, Antoine;
Colas, Jean‐Laurent;
Couffinhal, Thierry;
Salvo, Francesco

Publication type:

Article

Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran.

Published in:

IJ Pharmaceutical Research (IJPR), 2024, v. 23, n. 1, p. 1, doi. 10.5812/ijpr-146026

By:

Mollaee, Hosein;
Parashkouhi, Sadra Nadimi;
Fatemi, Behzad;
Seyedifar, Meysam;
Soleymani, Fatemeh

Publication type:

Article

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine.

Published in:

2021

By:

Manickam, Agaath Hedina;
Buture, Alina;
Tomkins, Esther;
Ruttledge, Martin

Publication type:

Case Study

Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 12, p. 1988, doi. 10.1002/psp4.13048

By:

Chen, Po‐Wei;
Karlsson, Mats O.;
Ueckert, Sebastian;
Pritchard‐Bell, Ari;
Hsu, Cheng‐Pang;
Dutta, Sandeep;
Ahamadi, Malidi

Publication type:

Article

Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.

Published in:

Brain Sciences (2076-3425), 2024, v. 14, n. 9, p. 948, doi. 10.3390/brainsci14090948

By:

Orlando, Bianca;
Egeo, Gabriella;
Aurilia, Cinzia;
Fiorentini, Giulia;
Barbanti, Piero

Publication type:

Article

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series.

Published in:

Brain Sciences (2076-3425), 2021, v. 11, n. 3, p. 370, doi. 10.3390/brainsci11030370

By:

Ornello, Raffaele;
Frattale, Ilaria;
Caponnetto, Valeria;
De Matteis, Eleonora;
Pistoia, Francesca;
Sacco, Simona;
Zoccolotti, Pierluigi

Publication type:

Article

Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2023.1257282

By:

Wenfang Sun;
Yali Li;
Binbin Xia;
Jing Chen;
Yang Liu;
Jingyao Pang;
Fang Liu;
Hua Cheng

Publication type:

Article

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.

Published in:

2019

By:

Xu, Yang;
Gabriel, Kristin;
Wang, Yi;
Zhou, Yanchen;
Eisele, Osaro;
Vutikullird, Apinya;
Mikol, Daniel D.;
Lee, Edward

Publication type:

journal article

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.

Published in:

Toxins, 2022, v. 14, n. 12, p. 847, doi. 10.3390/toxins14120847

By:

Argyriou, Andreas A.;
Dermitzakis, Emmanouil V.;
Xiromerisiou, Georgia;
Vikelis, Michail

Publication type:

Article

A Retrospective Analysis of Migraine Prophylaxis with Anti-CGRP Monoclonal Anti bodies at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.

Published in:

Neurologijos Seminarai, 2022, v. 26, n. 2, p. 71, doi. 10.15388/NS.2022.26.10

By:

Karpavičiūtė, V.;
Statkevičienė, K.;
Žemgulytė, G.

Publication type:

Article

Erenumabo veiksmingumas ir saugumas: realios klinikinės praktikos rezultatų palyginimas su klinikinių tyrimų duomenimis.

Published in:

Neurologijos Seminarai, 2021, v. 25, n. 3, p. 138, doi. 10.29014/ns.2021.19

By:

Dapkutë, A.;
Ryliðkienë, K.

Publication type:

Article

Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study.

Published in:

2021

By:

Dinh, Bui Bao Khanh;
Aziz, Waseem Hamed;
Terruzzi, Alessandro;
Krieger, Derk Wolfgang

Publication type:

journal article

Real-world experiences of migraine patients on Erenumab: a Kuwait single center cohort.

Published in:

Neurological Research, 2024, v. 46, n. 8, p. 772, doi. 10.1080/01616412.2024.2354618

By:

Al-Hashel, Jasem Youssef;
Alroughani, Raed;
Alshaf, Fatemah;
Ashkanani, Hasan Kh;
Akl, Amr;
AlMutairi, Ohood;
Alwazzan, Sawsan;
Ahmed, Samar Farouk

Publication type:

Article

Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.

Published in:

Neurological Research, 2021, v. 43, n. 11, p. 932, doi. 10.1080/01616412.2021.1940672

By:

Shi, Min;
Guo, Jun;
Li, Zhaoying;
Sun, Honghui;
Yang, Xuhong;
Yang, Dongdong;
Zhao, Huan

Publication type:

Article

Clinical predictors for efficacy of erenumab for migraine: a Registry for Migraine (REFORM) study.

Published in:

Brain Communications, 2025, v. 7, n. 2, p. 1, doi. 10.1093/braincomms/fcaf147

By:

Karlsson, William Kristian;
Ashina, Messoud;
Christensen, Rune Häckert;
Al-Khazali, Haidar Muhsen;
Ashina, Håkan

Publication type:

Article

THE ROLE OF CGRP MONOCLONAL ANTIBODIES IN MIGRAINE TREATMENT - EFFICACY, SAFETY, AND PERSPECTIVES FOR THE FUTURE: A SYSTEMATIC REVIEW.

Published in:

Medical Science Pulse, 2023, v. 17, n. 4, p. 1, doi. 10.5604/01.3001.0054.0879

By:

TYBULCZUK, BALBINA;
RUSINOWSKA, BARBARA;
WAWERSKA, JULIA

Publication type:

Article

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.

Published in:

PharmacoEconomics, 2021, v. 39, n. 3, p. 357, doi. 10.1007/s40273-020-00996-2

By:

Mahon, Ronan;
Lang, Andrea;
Vo, Pamela;
Huels, Jasper;
Cooney, Philip;
Danyliv, Andriy;
Vudumula, Umakanth;
Vadapalle, Sreelatha;
Maniyar, Farooq;
Goadsby, Peter J.

Publication type:

Article

Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A—real-world data from a preliminary cohort study.

Published in:

Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2024.1370503

By:

Koelsche, Tristan;
Nikolov, Petyo;
Koska, Valeria;
Ingwersen, Jens;
Jansen, Robin;
Arat, Ercan;
Meuth, Sven G.;
Albrecht, Philipp;
Lee, John-Ih

Publication type:

Article

Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years.

Published in:

International Journal of Clinical Pharmacy, 2024, v. 46, n. 6, p. 1317, doi. 10.1007/s11096-024-01758-2

By:

Pons-Fuster, E.;
Lozano-Caballero, O.;
Martín-Balbuena, S.;
Lucas-Ródenas, C.;
Mancebo-González, A.;
De Gorostiza-Frías, I.;
González-Ponce, C. M.

Publication type:

Article

Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.

Published in:

Neurology International, 2024, v. 16, n. 1, p. 274, doi. 10.3390/neurolint16010019

By:

Suliman, Reem;
Santos, Vanessa;
Al Qaisi, Ibrahim;
Aldaher, Batool;
Al Fardan, Ahmed;
Al Barrawy, Hajir;
Bader, Yazan;
Supena, Jonna Lyn;
Alejandro, Kathrina;
Alsaadi, Taoufik

Publication type:

Article

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Published in:

Therapeutics & Clinical Risk Management, 2022, v. 18, p. 359, doi. 10.2147/TCRM.S263825

By:

De Matteis, Eleonora;
Sacco, Simona;
Ornello, Raffaele

Publication type:

Article

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention.

Published in:

Journal of Anaesthesiology Clinical Pharmacology, 2020, v. 36, n. 1, p. 104, doi. 10.4103/joacp.JOACP_3_19

By:

Garg, Shuchita;
Vij, Malti;
Edward, Neeraj;
Vij, Brinder

Publication type:

Article

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans.

Published in:

Brain: A Journal of Neurology, 2023, v. 146, n. 12, p. 5224, doi. 10.1093/brain/awad261

By:

Do, Thien Phu;
Deligianni, Christina;
Amirguliyev, Sarkhan;
Snellman, Josefin;
Lopez, Cristina Lopez;
Al-Karagholi, Mohammad Al-Mahdi;
Guo, Song;
Ashina, Messoud

Publication type:

Article

Erenumab.

Published in:: Australian Prescriber, 2018, v. 41, n. 6, p. 201, doi. 10.18773/austprescr.2018.068
Publication type:: Article

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study.

Published in:

Pain & Therapy, 2024, v. 13, n. 6, p. 1659, doi. 10.1007/s40122-024-00658-7

By:

Gaul, Charly;
Gendolla, Astrid;
Holle, Dagny;
Göbel, Hartmut;
Koch, Mirja;
Baufeld, Caroline;
Weiss, Cordula

Publication type:

Article

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.

Published in:

Pain & Therapy, 2024, v. 13, n. 5, p. 1299, doi. 10.1007/s40122-024-00644-z

By:

Urman, Robert;
Princic, Nicole;
Vuvu, Fiston;
Patel, Leah B.;
Oh, Sam;
Chandler, David;
Hindiyeh, Nada;
Bensink, Mark E.

Publication type:

Article

Correction to: Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.

Published in:

2023

By:

Chandler, David;
Szekely, Christine;
Aggarwal, Shivani;
Cyprien, Lori;
Bensink, Mark

Publication type:

Correction Notice

Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review.

Published in:

Pain & Therapy, 2023, v. 12, n. 1, p. 251, doi. 10.1007/s40122-022-00452-3

By:

Blumenfeld, Andrew M.;
Kaur, Gavneet;
Mahajan, Anadi;
Shukla, Hemlata;
Sommer, Katherine;
Tung, Amy;
Knievel, Kerry L.

Publication type:

Article

First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention.

Published in:

Pain & Therapy, 2022, v. 11, n. 4, p. 1483, doi. 10.1007/s40122-022-00417-6

By:

Göbel, Carl H.;
Heinze, Axel;
Karstedt, Sarah;
Cirkel, Anna;
Münte, Thomas F.;
Göbel, Hartmut

Publication type:

Article

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.

Published in:

Pain & Therapy, 2021, v. 10, n. 2, p. 1551, doi. 10.1007/s40122-021-00319-z

By:

Chandler, David;
Szekely, Christine;
Aggarwal, Shivani;
Cyprien, Lori;
Bensink, Mark

Publication type:

Article

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.

Published in:

Pain & Therapy, 2021, v. 10, n. 2, p. 809, doi. 10.1007/s40122-021-00264-x

By:

Blumenfeld, Andrew M.;
Frishberg, Benjamin M.;
Schim, Jack D.;
Iannone, Ashley;
Schneider, Gary;
Yedigarova, Larisa;
Manack Adams, Aubrey

Publication type:

Article

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.

Published in:

Neurology & Therapy, 2023, v. 12, n. 6, p. 1993, doi. 10.1007/s40120-023-00538-w

By:

Kitamura, Shigekazu;
Takeshima, Takao;
Yui, Daishi;
da Silva Lima, Gabriel Paiva;
Koukakis, Reija;
Peng, Cheng;
Yoshida, Ryuji;
Numachi, Yotaro;
Hasebe, Miki

Publication type:

Article

Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.

Published in:

Neurology & Therapy, 2023, v. 12, n. 2, p. 651, doi. 10.1007/s40120-023-00453-0

By:

Seo, Jaein;
Tervonen, Tommi;
Ueda, Kaname;
Zhang, Dian;
Danno, Daisuke;
Tockhorn-Heidenreich, Antje

Publication type:

Article